<DOC>
	<DOCNO>NCT02693093</DOCNO>
	<brief_summary>The purpose study determine safety efficacy NI-03 .</brief_summary>
	<brief_title>A Dose Ranging Study Evaluating Efficacy Safety NI-03</brief_title>
	<detailed_description>The primary objective Single-Dose Phase ass pharmacokinetics ( PK ) safety single dose NI-03 administer dos 100 mg , 200 mg 300 mg subject pancreatitis . The primary objective Double-Blind Phase study determine efficacy , PK safety three dose NI-03 ( 100 mg , 200 mg 300 mg ) compare placebo administer three time daily ( TID ) 28 consecutive day subject chronic pancreatitis .</detailed_description>
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Pancreatitis , Chronic</mesh_term>
	<criteria>To eligible participate study , subject must meet follow criterion Screening : 1 . Males female age 18 80 year , inclusive , time consent 2 . Ability communicate effectively clinic site staff , ability willingness comply study schedule , restriction , requirement 3 . Institutional Review Board ( IRB ) approve write informed 4 . Diagnosis chronic pancreatitis 5 . Baseline average daily bad pain score must minimum 4 use Numeric Rating ScaleNRS 7day runin period 6 . Patients nonopioid analgesic regimen expect remain stable study period , opioid regimen morphineequivalent dose 40 mg daily . To eligible participate study , subject must meet following criterion : 1 . Any clinically significant medical condition 2 . Treatment investigational product within 14 day Day 1 ( 5 drug halflives 5 drug halflives expect exceed 14 day ) Day 7 3 . Major surgery within 90 day Day 1 4 . History presence clinically significant cardiovascular disease 5 . History cancer , except nonmelanoma skin cancer , within 5 year study enrollment , 6 . History endoscopic intervention within previous 3 month 7 . History illicit drug abuse ( i.e . use 'illegal ' drug within 6 month ) 8 . Active heavy alcohol use ( defined 2 alcoholic drink per day 14 alcoholic drink per week ) 9 . Inadequate venous access 10 . Significant blood loss , donation â‰¥450 mL blood , blood blood product transfusion within 7 day Day 1 11 . History presence hepatitis B ( surface antigen positivity ) , hepatitis C human immunodeficiency virus ( HIV ) antibody 12 . Active infection within 30 day Day 1 13 . Pregnant , plan become pregnant breast feed 14 . Positive serum pregnancy test result Screening Day 1 15 . Active major psychiatric illness require change treatment within 3 month would confound pain assessment 16 . History seizure within last 12 month 17 . 16.17 . Use anticonvulsant , antipsychotic , systemic steroid , immunosuppressant therapy antimalarial 18 . Presence generalize pain syndrome apart chronic pancreatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>